Objective of this study is to show that a laboratory alcohol self-administration method can predict the therapeutic potential of new compounds to reduce relapse in alcohol-dependent patients.~The 'TEMA translates several animal behavioral paradigms of alcohol self-administration into corresponding human experiments.~We will investigate the opiate antagonist Naltrexone, whose anti-relapse effect is well documented, as a reference drug for validation.~Main objective:~With TEMA (test system for development of medications for alcoholism ) it can be shown, that naltrexone administration reduces the willingness to perform work for alcohol infusion in a laboratory experiment.~Secondary objectives:~administration of naltrexone in comparison to placebo leads to a reduction of alcohol craving and real-life drinking~administration of naltrexone in comparison to placebo leads to reduction of the CDT-Level~administration of naltrexone in comparison to placebo leads to a change in perception of subjective alcohol effects~the effectiveness of naltrexone can be predicted by the A118G polymorphism of the OPRM1~administration of naltrexone changes the baseline and alcohol-induced ability of motor inhibition~administration of naltrexone changes the baseline and alcohol-induced regional cerebral perfusion~administration of naltrexone changes the baseline and alcohol-induced cerebral resting state activity~changes of alcohol effects to the brain activity induced by naltrexone in comparison to placebo correlate with effects of naltrexone on the willingness to work for alcohol self-administration
Using theTEMA (test system for development of medications for alcoholism) it can be shown, that naltrexone administration reduces the willingness to perform work for alcohol infusion in a laboratory experiment.